Literature DB >> 19718467

Two cases of congenital dysfibrinogenemia associated with thrombosis - Fibrinogen Praha III and Fibrinogen Plzen.

Roman Kotlín1, Zuzana Reicheltová, Martin Malý, Jirí Suttnar, Alzbeta Sobotková, Peter Salaj, Jana Hirmerová, Tomás Riedel, Jan E Dyr.   

Abstract

Congenital dysfibrinogenemia is a rare disease characterised by inherited abnormality in the fibrinogen molecule, resulting in functional defects. Two patients, a 26-year-old woman and a 61-year-old man, both with history of thrombotic events, had abnormal coagulation test results. DNA sequencing showed the heterozygous gamma Y363N mutation (Fibrinogen Praha III) and the heterozygous Aalpha N106D mutation (Fibrinogen Plzen), respectively. Fibrin polymerisation, after addition of either thrombin or reptilase, showed remarkably delayed polymerisation in both cases. Fibrinolysis experiments showed slower tPA initiated lysis of clots. SDS-PAGE did not show any difference between normal and Praha III and Plzen fibrinogens. Both mutations had a significant effect on platelet aggregation. In the presence of either ADP or TRAP, both mutations caused the decrease of platelet aggregation. SEM revealed abnormal clot morphology, with a large number of free ends and narrower fibres of both fibrin Praha III and Plzen. Praha III mutation was situated in the polymerisation pocket "a". The replacement of the bulky aromatic side chain of tyrosine by the polar uncharged small side chain of asparagine may lead to a conformational change, possibly altering the conformation of the polymerisation pocket. The Plzen mutation is situated in the coiled-coil connector and this replacement of polar uncharged asparagine residue by polar acidic aspartate changes the alpha-helical conformation of the coiled-coil connector; and may destabilise hydrogen bonds in its neighborhood. Although both mutations are situated in different regions of the molecule, both mutations have a very similar effect on fibrinogen functions and both are connected with thromboses.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19718467     DOI: 10.1160/TH08-11-0771

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  7 in total

1.  Two novel fibrinogen variants in the C-terminus of the Bβ-chain: fibrinogen Rokycany and fibrinogen Znojmo.

Authors:  Roman Kotlín; Zuzana Reicheltová; Jirí Suttnar; Peter Salaj; Ingrid Hrachovinová; Tomás Riedel; Martin Malý; Milan Oravec; Jan Kvasnicka; Jan Evangelista Dyr
Journal:  J Thromb Thrombolysis       Date:  2010-10       Impact factor: 2.300

Review 2.  Thrombosis in Inherited Fibrinogen Disorders.

Authors:  Wolfgang Korte; Man-Chiu Poon; Alfonso Iorio; Michael Makris
Journal:  Transfus Med Hemother       Date:  2017-03-14       Impact factor: 3.747

3.  Dysfibrinogenemia with Subgaleal Hematoma: An Unusual Presentation.

Authors:  Manika Khare; Vijay Kumar; Sadhna Marwah; A S Nigam; Gurdeep Buxi
Journal:  Indian J Hematol Blood Transfus       Date:  2015-10-26       Impact factor: 0.900

Review 4.  Inherited risk factors for venous thromboembolism.

Authors:  Ida Martinelli; Valerio De Stefano; Pier M Mannucci
Journal:  Nat Rev Cardiol       Date:  2014-01-14       Impact factor: 32.419

5.  Why dysfibrinogenaemias still matter.

Authors:  John W Weisel
Journal:  Thromb Haemost       Date:  2009-09       Impact factor: 5.249

6.  A novel fibrinogen mutation: FGA g. 3057 C > T (p. Arg104 > Cys) impairs fibrinogen secretion.

Authors:  R Marchi; M Linares; H Rojas; A Ruiz-Sáez; M Meyer; A Casini; S O Brennan
Journal:  BMC Hematol       Date:  2017-12-22

Review 7.  Heterogeneity of Genotype-Phenotype in Congenital Hypofibrinogenemia-A Review of Case Reports Associated with Bleeding and Thrombosis.

Authors:  Monika Brunclikova; Tomas Simurda; Jana Zolkova; Miroslava Sterankova; Ingrid Skornova; Miroslava Dobrotova; Zuzana Kolkova; Dusan Loderer; Marian Grendar; Jan Hudecek; Jan Stasko; Peter Kubisz
Journal:  J Clin Med       Date:  2022-02-18       Impact factor: 4.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.